http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-20025651-D0

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
filingDate 2002-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cabc765bf3c49b959b63d0a7d996af7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4614955bb8a480b463637fda3a96d66b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cd896d02f0a225e704543422bea06d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c563ae7386f419bd6ede49d92d21ef4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afabe4132e4fc910f8841120eca5000d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6421bffda7ffbc13e5b8958d0aa2586e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d19bbca22f41ebcde62451b2573d8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93635decfd4e628ef854d34a0c08a8a9
publicationDate 2002-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NO-20025651-D0
titleOfInvention Adenosine A2A Receptor Antagonists
abstract Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, cycloalkenyl, or heteroaryl; X is alkylene or -C(O)CH2-; Y is -N(R2)CH2CH2N(R)3)-, -OCH2CH2N(R2)-, -O-, -S-, -CH2S-, -(CH2)2-NH-, or optionally substituted m and n are 2-3, and Q is nitrogen or optionally substituted carbon; and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, R6-C(O)-, R6-SO2-, R6-OC(O)-, R7-N(R8)-C(O)-, R7-N(R8)-C(S)-, phenyl-CH(OH)-, or phenyl-C(=NOR2)-; or when Q is CH, phenylamino or pyridylamino; or Z and Y together are substituted piperidinyl or substituted phenyl; and R2, R3, R6, R7, and R8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them; also disclosed are a processes for preparing intermediates useful for preparing compounds of formula I.
priorityDate 2000-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395511
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID947

Total number of triples: 38.